Polycythemia differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polycythemia}} | {{Polycythemia}} | ||
{{CMG}} | {{CMG}} {{AE}}{{SSH}} | ||
==Overview== | |||
== | ==Differential Diagnosis== | ||
Polycythemia must be differentiated from a variety of other conditions.<ref name="pmid25611051">{{cite journal| author=Tefferi A, Barbui T| title=Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. | journal=Am J Hematol | year= 2015 | volume= 90 | issue= 2 | pages= 162-73 | pmid=25611051 | doi=10.1002/ajh.23895 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25611051 }} </ref><ref name="pmid16879015">{{cite journal| author=Sanchez S, Ewton A| title=Essential thrombocythemia: a review of diagnostic and pathologic features. | journal=Arch Pathol Lab Med | year= 2006 | volume= 130 | issue= 8 | pages= 1144-50 | pmid=16879015 | doi=10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16879015 }} </ref><ref name="pmid24729196">{{cite journal| author=Jabbour E, Kantarjian H| title=Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. | journal=Am J Hematol | year= 2014 | volume= 89 | issue= 5 | pages= 547-56 | pmid=24729196 | doi=10.1002/ajh.23691 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24729196 }} </ref> | |||
== | {| | ||
*Acute | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease | ||
* | ! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mutation | ||
* | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ||
*[[ | ! colspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ||
* | ! colspan="6" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Laboratory findings | ||
*[[ | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Treatment | ||
*[[ | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
*[[ | |- | ||
*[[ | ! colspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | ||
* | ! colspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs | ||
*[[ | ! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC | ||
*[[ | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Erythropoietin level | ||
*[[ | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ||
*[[Primary | |- | ||
* | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |JAK2 mutation | ||
*[[ | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CALR mutation | ||
*[[ | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fatigue | ||
*[[ | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Headache | ||
*[[ | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ||
*[[ | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pain | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other symptoms | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hb | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |RBC | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt | |||
|- | |||
! align="center" style="background:#DCDCDC;" |[[Polycythemia vera (PV)]] | |||
| align="center" style="background:#F5F5F5;" |> 95% | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" |Autonomous erythrocyte production | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Erythromelagia]] | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Stroke]]-like symptoms | |||
| align="center" style="background:#F5F5F5;" |[[Ruddy face]] | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |NA | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ RBC mass | |||
| align="center" style="background:#F5F5F5;" |Nl to ↑ | |||
| align="center" style="background:#F5F5F5;" |Nl to ↑ | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Aspirin]] | |||
* [[Ruxolitinib]] | |||
* [[Hydroxyurea]] | |||
* [[Phlebotomy]] | |||
* [[Interferon-alpha]] | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Stroke]] | |||
* [[Venous thrombosis]] | |||
* [[Myelofibrosis]] | |||
* [[Acute leukemia]] | |||
|- | |||
! align="center" style="background:#DCDCDC;" |[[Essential thrombocythemia]] (ET) | |||
| align="center" style="background:#F5F5F5;" |50% | |||
| align="center" style="background:#F5F5F5;" | +/- | |||
| align="left" style="background:#F5F5F5;" | | |||
* Clonal proliferation of megakaryocytes | |||
* Excess [[platelet]] production | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | + (paradoxical) | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="left" style="background:#F5F5F5;" | | |||
* Stroke-like symptoms | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |[[Bruises]] | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" |↑ (dysfunctional platelets) | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Aspirin]] | |||
* [[Hydroyurea]] | |||
* [[Anagrelide]] | |||
| align="left" style="background:#F5F5F5;" | | |||
* Acquired [[von Willebrand disease]] | |||
* [[Myelofibrosis]] | |||
* [[Acute leukemia]] | |||
|- | |||
! align="center" style="background:#DCDCDC;" |[[Chronic myeloid leukemia]] (CML) | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="left" style="background:#F5F5F5;" | | |||
* Reciprocal translocation of chromosomes 9 and 22 | |||
* Production of BCR-Abl kinase | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |[[Abdominal pain]] | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" |Elevated metamyelocytes and other [[white blood cells]] at various stages of maturation | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Imatinib]] | |||
* [[Dasatinib]] | |||
* [[Bosutinib]] | |||
* [[Nilotinib]] | |||
* [[Ponatinib]] for T315I kinase domain mutation | |||
* [[Interferon-alpha]] | |||
| align="left" style="background:#F5F5F5;" | | |||
* Can appear similar to [[leukemoid reaction]] | |||
|- | |||
! align="center" style="background:#DCDCDC;" |[[Primary myelofibrosis]] (PMF) | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="left" style="background:#F5F5F5;" | | |||
* Clonal disorder of [[megakaryocytes]] | |||
* Excess production [[TGF-beta]] and [[collagen]] | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |[[Abdominal pain]] | |||
| align="left" style="background:#F5F5F5;" | | |||
* Early satiety | |||
| align="center" style="background:#F5F5F5;" |Pallor | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Hepatomegaly]] | |||
* [[Bruising]] | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Hydroxyurea]] | |||
* [[Stem cell transplant]] | |||
* [[Ruxolitinib]] | |||
| align="left" style="background:#F5F5F5;" | | |||
* Variable risk for development of [[acute leukemia]] | |||
|- | |||
! align="center" style="background:#DCDCDC;" |Secondary polycythemia due to chronic hypoxia | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Congestive heart failure]] (CHF) | |||
* [[Interstitial lung disease]] (ILD) | |||
* [[Obstructive sleep apnea]] (OSA) | |||
* Smoking | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="center" style="background:#F5F5F5;" |Depends on etiology | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Shortness of breath]] | |||
| align="center" style="background:#F5F5F5;" |[[Cyanosis]] | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Crackles]] | |||
* [[Tachypnea]] | |||
* [[Tachycardia]] | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="left" style="background:#F5F5F5;" | | |||
* Treatment of underlying cause | |||
| align="left" style="background:#F5F5F5;" | | |||
* Variable manifestations given the diverse etiologies | |||
|- | |||
! align="center" style="background:#DCDCDC;" |Secondary polycythemia due to [[erythropoietin]] producing tumor | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="left" style="background:#F5F5F5;" | | |||
* Renal cell carcinoma | |||
* Hepatocellular carcinoma | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="center" style="background:#F5F5F5;" |Depends on etiology | |||
| align="center" style="background:#F5F5F5;" |Depends on etiology | |||
| align="center" style="background:#F5F5F5;" |Chronically ill | |||
| align="center" style="background:#F5F5F5;" | +/- | |||
| align="center" style="background:#F5F5F5;" | +/- | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="center" style="background:#F5F5F5;" | | |||
* [[Hepatomegaly]] | |||
* [[Bruising]] | |||
| align="center" style="background:#F5F5F5;" |↑/↓ | |||
| align="center" style="background:#F5F5F5;" |↑/↓ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" | | |||
| align="center" style="background:#F5F5F5;" | | |||
* Surgery | |||
* Chemotherapy | |||
| align="center" style="background:#F5F5F5;" | | |||
* Variable manifestations given the diverse etiologies | |||
|- | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |JAK2 mutation | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CALR mutation | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fatigue | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Headache | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pain | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other symptoms | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hb | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |RBC | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Erythropoietin level | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Treatment | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | |||
|} | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 15:12, 21 August 2018
Polycythemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Polycythemia differential diagnosis On the Web |
American Roentgen Ray Society Images of Polycythemia differential diagnosis |
Risk calculators and risk factors for Polycythemia differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Differential Diagnosis
Polycythemia must be differentiated from a variety of other conditions.[1][2][3]
Disease | Mutation | Etiology | Clinical manifestations | Laboratory findings | Treatment | Associated findings | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Signs | CBC | Erythropoietin level | PBS | |||||||||||||||||
JAK2 mutation | CALR mutation | Fatigue | Headache | Bleeding | Pain | Other symptoms | Appearance | Fever | Tenderness | Splenomegaly | Other signs | Hb | RBC | WBC | Plt | ||||||
Polycythemia vera (PV) | > 95% | Autonomous erythrocyte production | + | - |
|
Ruddy face | - | - | + | NA | ↑ | ↑ RBC mass | Nl to ↑ | Nl to ↑ | |||||||
Essential thrombocythemia (ET) | 50% | +/- |
|
+ | + (paradoxical) |
|
+ | Bruises | ↑ (dysfunctional platelets) | ||||||||||||
Chronic myeloid leukemia (CML) | - | - |
|
+ | + | + | Abdominal pain | + | + | ↑ | ↑ | ↑ | ↑ | Elevated metamyelocytes and other white blood cells at various stages of maturation |
| ||||||
Primary myelofibrosis (PMF) |
|
+ | + | Abdominal pain |
|
Pallor | + | ↓ | ↓ | ↓ | ↓ |
| |||||||||
Secondary polycythemia due to chronic hypoxia | - | - |
|
+ | + | - | Depends on etiology | Cyanosis | - | ↑ | ↑ | Nl | Nl | ↑ |
|
| |||||
Secondary polycythemia due to erythropoietin producing tumor | - | - |
|
+ | - | - | Depends on etiology | Depends on etiology | Chronically ill | +/- | +/- | - | ↑/↓ | ↑/↓ | Nl | ↑ | ↑ |
|
| ||
Disease | JAK2 mutation | CALR mutation | Etiology | Fatigue | Headache | Bleeding | Pain | Other symptoms | Appearance | Fever | Tenderness | Splenomegaly | Other signs | Hb | RBC | WBC | Plt | Erythropoietin level | PBS | Treatment | Associated findings |
References
- ↑ Tefferi A, Barbui T (2015). "Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management". Am J Hematol. 90 (2): 162–73. doi:10.1002/ajh.23895. PMID 25611051.
- ↑ Sanchez S, Ewton A (2006). "Essential thrombocythemia: a review of diagnostic and pathologic features". Arch Pathol Lab Med. 130 (8): 1144–50. doi:10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2. PMID 16879015.
- ↑ Jabbour E, Kantarjian H (2014). "Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management". Am J Hematol. 89 (5): 547–56. doi:10.1002/ajh.23691. PMID 24729196.